Physician profile
George C James
NPI 1992771455
$3,181.98
in general payments reported to CMS, 2019-2025
21 companies · $530 in 2025
The $530 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $657 · 2020: $518 · 2021: $220 · 2022: $351 · 2023: $354 · 2024: $553 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,359 · Education: $76.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,359.44 |
| Education | $76.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $630.30 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $571.61 | 2019-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $359.57 | 2022-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $278.05 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Abbvie INC. | $247.80 | 2022-2025 | |
| Lundbeck LLC | $207.72 | 2021-2025 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $166.58 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $152.00 | 2023-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $116.84 | 2020-2022 | |
| Axsome Therapeutics, INC. | $90.40 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $60.80 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $56.51 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $55.34 | 2024-2025 | Cobenfy |
| Eisai INC. | $36.68 | 2020 | |
| Allergan, INC. | $28.56 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $26.73 | 2019 | |
| Noven Therapeutics, LLC | $22.48 | 2020 | |
| Jazz Pharmaceuticals INC. | $21.52 | 2020 | |
| Merck Sharp & Dohme LLC | $19.25 | 2020 | |
| Braeburn INC. | $17.55 | 2024 | Brixadi |
| Abbott Laboratories | $15.69 | 2025 | Jot Dx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.